Genetically proxied inhibition of L-2-hydroxyglutarate dehydrogenase and the risk of coronary artery disease: A Mendelian randomization study

Euijun Song, M.D.

Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence: drjunsong@gmail.com (Euijun Song)

Conflicts of interest: All authors have no financial conflicts of interest to declare.

Abstract

Background: L-2-hydroxyglutarate dehydrogenase (L2HGDH) deletion-induced L-2-hydroxyglutarate accumulation plays a cardioprotective role in hypoxic conditions. However, there has been no causal evidence in real-world clinical data. We aimed to examine the causal effects of *L2HGDH* inhibition on coronary artery disease (CAD) and myocardial infarction (MI) using Mendelian randomization (MR) analysis.

Methods: We used nine *L2HGDH*-proxied genetic variants associated with blood 2-hydroxyglutarate levels as genetic instruments, and performed two-sample MR analysis using the CARDIoGRAMplusC4D meta-analysis datasets of CAD (60,801 CAD cases and 123,504 controls) and MI (34,541 MI cases and 261,984 controls).

Results: Genetically proxied inhibition of *L2HGDH* associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (odds ratio [OR] 0.486, 95% confidence interval [CI] 0.242–0.977, P=0.043) but was not associated with the risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). This potentially causal association between *L2HGDH* inhibition and CAD was unlikely to be biased by horizontal pleiotropy, whereas there might be a weak instrument bias.

Conclusion: Our MR analysis suggests the potential association between genetically proxied inhibition of *L2HGDH* and CAD. Our findings may have therapeutic implications for L2HGDH inhibitors in CAD, and further large-scale clinical studies are needed.

Keywords: L-2-hydroxyglutarate dehydrogenase; coronary artery disease; therapeutics; Mendelian randomization; metabolism

1. Introduction

L-2-hydroxyglutarate plays a pivotal role in cytoplasmic and mitochondrial energy metabolism to maintain redox regulation [1]. Hypoxia increases cellular L-2-hydroxyglutarate, which is produced from α-ketoglutarate by malate dehydrogenase [1-3]. L-2-hydroxyglutarate dehydrogenase (L2HGDH) is the only enzyme known to oxidize L-2-hydroxyglutarate back to α-ketoglutarate [2, 4]. In experiments, *L2HGDH* ablation increases the accumulation of L-2-hydroxyglutarate in hypoxia [2, 5]. L-2-hydroxyglutarate has been known to protect heart tissue from oxidative stress in response to hypoxia [5]. Since coronary artery disease (CAD) leads to ischemic injury and ischemia-reperfusion injury, L-2-hydroxyglutarate may play a protective role in CAD and ischemic myocardial injury.

Metabolic remodeling plays a key role in the pathobiology of CAD and myocardial infarction (MI) [5-7]. Recently, He and colleagues [5] discovered that genetic *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation shows cardioprotective effects under ischemic conditions in mice. They found that L-2-hydroxyglutarate accumulation shifts glucose metabolisms from glycolysis to the pentose phosphate pathway in response to low-flow ischemia or ischemia-reperfusion. This metabolic shift indicates that *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation could reduce ischemic myocardial damage by eliminating reactive oxygen species. The experiments suggest that *L2HGDH* is a potential therapeutic target for oxidative stress-related cardiovascular diseases, such as CAD and MI. However, there has been no prospective clinical trial yet.

One genetic epidemiological approach for testing the causal effects of drug targets on complex diseases is the Mendelian randomization (MR) method [8-12]. MR methods can estimate the causal effects of putative risk factors based on germline genetic variation in the population, without conducting a randomized controlled trial. Using the drug-target MR framework, Ference and colleagues [8] determined the causal associations of ATP citrate lyase (ACLY) and HMG-CoA reductase (HMGCR) inhibitions with the risk of cardiovascular disease. Similarly, MR approaches could identify the potentially causal associations of genetically proxied inhibition of cardiovascular drug targets with cancers, neuropsychiatric diseases, and cognitive function [9-12].

Here, we conduct a two-sample MR study to assess putative causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI (Figure 1). We construct genetic instruments for *L2HGDH* that are associated with blood 2-hydroxyglutarate levels. We then perform MR analysis to test whether this genetic instrument is causally associated with CAD and MI using large-scale genome-wide association study (GWAS) datasets.

2. Methods

2.1. Mendelian randomization study design

As illustrated in Figure 1, we designed a two-sample MR study to determine putative causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI. We first

82 constructed the genetic instruments for *L2HGDH* to mimic pharmacological/genetic
83 perturbation of *L2HGDH* for increasing L-2-hydroxyglutarate levels. Due to the limited
84 availability of GWAS data for L-2-hydroxyglutarate levels, we constructed the genetic
85 instruments that are associated with 2-hydroxyglutarate level instead. We then
86 performed the Mendelian randomization analysis to determine potential causal
87 associations between the genetic instruments for *L2HGDH* and CAD using large-scale
88 GWAS summary statistics datasets.
89
90 **2.2. Genetic instruments for genetically proxied inhibition of *L2HGDH***
91 We obtained the GWAS summary statistics for human blood metabolome from Shin et
92 al [13]. Shin et al. [13] analyzed >400 blood metabolites from the KORA and TwinsUK
93 European population datasets using the Metabolon platform. Since the Metabolon
94 platform could not distinguish L-2-hydroxyglutarate from D-2-hydroxyglutarate, we
95 alternatively used the GWAS data for 2-hydroxyglutarate levels (accessed from
96 https://gwas.mrcieu.ac.uk/) to construct the genetic instruments for *L2HGDH*.
97
98 L2HGDH is the only enzyme known to catabolize L-2-hydroxyglutarate in human cells,
99 and L2HGDH inhibition increases L-2-hydroxyglutarate levels in experiments [1, 2].
100 Since 2-hydroxyglutarate includes both L-2-hydroxyglutarate and D-2-hydroxyglutarate,
101 we only considered *L2HGDH*-proxied genetic variants to mainly reflect L-2-
102 hydroxyglutarate levels. We constructed the genetic instruments for *L2HGDH* by
103 recruiting genetic variants within ± 500 kb from the *L2HGDH* gene that are associated
104 with blood 2-hydroxyglutarate level ($P<0.05$) and that are also in low linkage

105 disequilibrium (r^2<0.3, with the default clumping window size of 10000 kb) [8]. The
106 characteristics of genetic variants proxied to *L2HGDH* are shown in Table S1. Since
107 there was no genome-wide significant variant near the *L2HGDH* gene (Table S2), we
108 adopted weak P-value and r^2 thresholds previously suggested by Ference and
109 colleagues [8]. The SNPs and *L2HGDH* gene were analyzed based on the GRCh37
110 (hg19) human genome reference (Figure S1). The PhenoScanner V2
111 (http://www.phenoscanner.medschl.cam.ac.uk/, accessed on Feb 6, 2023) was used to
112 identify pleiotropic variants (Table S3).
113

114 **2.3. Data sources for CAD and MI**

115 The GWAS summary statistics for CAD was obtained from the CARDIoGRAMplusC4D
116 (Coronary Artery DIsease Genome-wide Replication and Meta-analysis plus Coronary
117 Artery Disease) 1000 Genomes-based GWAS meta-analysis study
118 (http://www.cardiogramplusc4d.org) [14]. The CARDIoGRAMplusC4D GWAS meta-
119 analysis dataset included genetic associations from 60,801 CAD cases and 123,504
120 controls mostly of European ancestry. The case status was defined by diagnosis of
121 CAD, including MI, acute coronary syndrome, chronic stable angina, and coronary
122 stenosis >50% [14]. In addition, the MI GWAS summary statistics was obtained from the
123 same CARDIoGRAMplusC4D meta-analysis study (34,541 MI cases and 261,984
124 controls). All the MI cases are a subpopulation of the CAD cases [14].
125

126 **2.4. Mendelian randomization and statistical analysis**

For MR analysis, the instrument strength was measured using the F-statistic. The F-statistic less than 10 indicates weak instruments. We used the inverse-variance weighted (IVW), weighted median, maximum likelihood, MR-PRESSO [15], Radial-MR [16], and MR-RAPS [17] methods to evaluate the putative causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI. The heterogeneity between SNPs was evaluated by Cochran's Q test [18]. We also performed the MR Steiger directionality test to determine the directionality of causality [19]. To assess potential directional and horizontal pleiotropy, we used the MR-Egger intercept test and MR-PRESSO methods. The leave-one-out sensitivity analysis and Radial-MR were used to detect potential outlying genetic variants. $P<0.05$ was considered statistically significant. All MR analyses were performed in R (version 4.1.2, https://www.r-project.org/) with the packages TwoSampleMR, MRPRESSO, and RadialMR.

3. Results

3.1. Genetic instruments for *L2HGDH*

We first constructed the genetic instruments proxied to *L2HGDH* that are associated with blood 2-hydroxyglutarate levels ($P<0.05$) and that are also in low linkage disequilibrium ($r^2<0.3$; Table S1). Since there was no genome-wide significant variant associated with 2-hydroxyglutarate levels near the *L2HGDH* gene (Table S2), we adopted a loose significance threshold of 0.05 to construct instruments for genetically proxied inhibition of *L2HGDH* [8]. These genetic instruments mimic genetic or pharmacological inhibition of *L2HGDH* for increasing blood 2-hydroxyglutarate levels

150 (Figure 1). The genetic instruments have the mean F-statistic of 7.661, indicating that
151 there might be a weak instrument bias in our MR analysis. The genetic instruments are
152 not associated with possible confounders or cardiovascular diseases/traits (Table S3).
153

154 **3.2. Association of genetically proxied inhibition of *L2HGDH* with CAD and MI**

155 We performed a two-sample MR analysis using the CARDIoGRAMplusC4D GWAS
156 meta-analysis dataset of CAD (60,801 CAD cases and 123,504 controls). As highlighted
157 in Table 1, the IVW method showed that genetically proxied inhibition of *L2HGDH*
158 associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (OR
159 0.486, 95% CI 0.242–0.977, P=0.043). There was no significant evidence of
160 heterogeneity (Cochran's Q-statistic=5.757, P=0.674). The radial IVW, weighted
161 median, and maximum likelihood methods also showed directionally similar estimates
162 (Table 1). The MR-RAPS method indicated that there might be a slightly weak
163 instrument bias (OR 0.460, 95% CI 0.202–1.046, P=0.064). The MR Steiger
164 directionality test confirmed the direction of the causality (P<0.001).
165

166 To assess potential directional horizontal pleiotropy, we used the MR-Egger and MR-
167 PRESSO methods. The MR-Egger intercept test determined that 9 genetic variants for
168 *L2HGDH* showed no evidence for significant pleiotropy (intercept=-0.014, P=0.396).
169 The MR-PRESSO global test also confirmed no significant horizontal pleiotropy with no
170 outlying genetic variants (P=0.715). In addition, the leave-one-out sensitivity analysis
171 showed that removing individual genetic variants did not substantially change the
172 estimated causal effect of genetically proxied inhibition of *L2HGDH* (Table S4). The

173 radial IVW method further confirmed no evidence of outlying genetic variants (Figure
174 S2). Taken together, the sensitivity analyses provide no significant evidence for
175 pleiotropic effects, which could bias the MR analysis.
176
177 As a subpopulation of the CAD cases, we also examined the putative causal
178 association between *L2HGDH* inhibition and MI using the CARDIoGRAMplusC4D meta-
179 analysis dataset of MI (34,541 MI cases and 261,984 controls). Using IVW, we found
180 that genetically proxied inhibition of *L2HGDH* was not significantly associated with the
181 risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). The MR-Egger intercept and MR-
182 PRESSO global tests indicated no significant pleiotropy (Table 1), and the radial plot
183 indicated no evidence of outlying variants (Figure S2).
184
185
186 **4. Discussion**
187 To our knowledge, this is the first MR study to demonstrate the potentially causal
188 association between genetically proxied inhibition of *L2HGDH* and CAD. Using two-
189 sample MR analyses, we revealed that genetically proxied inhibition of *L2HGDH* was
190 significantly associated with the decreased risk of CAD. The multiple MR sensitivity
191 analyses confirmed that this potential causal association was unlikely to be biased by
192 horizontal pleiotropy. Our findings suggests that genetic/pharmacological targeting of
193 *L2HGDH* may decrease the risk of CAD by increasing blood 2-hydroxyglutarate levels.
194 Since our genetic instruments are not directly associated with L-2-hydroxyglutarate

levels and there might be a weak instrument bias, further large-scale GWAS studies are needed to obtain more robust and reliable MR results.

In the previous experimental study, *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation protects the heart from redox stress, which plays a key role in myocardial ischemic injury [5]. However, there has been no clinical trial to validate this potential cardioprotective effect of *L2HGDH* inhibition. Using large-scale MR, we revealed that genetically proxied inhibition of *L2HGDH* could potentially decrease the risk of CAD but was not significantly associated with MI *per se* (Table 1). In our MR study, the CAD cases include MI, acute coronary syndrome, coronary atherosclerosis, and chronic ischemic heart diseases. Therefore, our findings suggest that *L2HGDH* inhibition may play a cardioprotective role in not only being limited to myocardial ischemic damage, but also in the primary prevention of CAD. The mechanisms underlying the potential preventive effects of *L2HGDH* inhibition on CAD should be further investigated.

Due to the limited availability of GWAS data on blood metabolome, we constructed genetic instruments based on blood 2-hydroxyglutarate levels, including its two enantiomers L-2-hydroxyglutarate and D-2-hydroxyglutarate. D-2-hydroxyglutarate has been known to be an oncometabolite in certain types of rare cancers [20, 21]. To minimize the effects of D-2-hydroxyglutarate in our MR analysis, we constructed the genetic instruments only proxied to the *L2HGDH* gene. In experiments, L-2-hydroxyglutarate is the majority of 2-hydroxyglutarate, and *L2HGDH* but not D2HGDH knockdown increases the concentration of 2-hydroxyglutarate [1, 2]. Additionally,

218 L2HGDH is the only reported enzyme that metabolizes L-2-hydroxyglutarate. Therefore,
219 our approach would mainly reflect *L2HGDH* inhibition-related L-2-hydroxyglutarate
220 levels; however, large-scale GWAS data of blood L-2-hydroxyglutarate levels is
221 essential to obtain more robust and reliable MR results. Since L-2-hydroxyglutarate is
222 also a putative oncometabolite in renal cell carcinoma [22, 23], further
223 epidemiological/clinical studies are warranted to determine the potential side effects of
224 *L2HGDH* inhibition.
225
226 A critical limitation of this study is that we adopted a loose P-value threshold of 0.05 to
227 build the genetic instruments [8]. When we used the genome-wide significance
228 threshold, there was no genetic variant associated with blood 2-hydroxyglutarate levels,
229 near the *L2HGDH* gene (Table S2). Since L2HGDH is the only enzyme known to
230 metabolize L-2-hydroxyglutarate, we only considered *L2HGDH*-proxied variants to
231 reflect the physiological effects of *L2HGDH* inhibition on L-2-hydroxyglutarate levels [1,
232 2]. In addition, we did not perform any replication analysis in non-European populations,
233 though the CARDIoGRAMplusC4D is the largest consortium study of CAD. Another
234 critical limitation is the underlying overlap between exposure and outcome datasets, as
235 the CARDIoGRAMplusC4D includes KORA (also known as GerMIFS III) and TwinsUK
236 (part of the PROCARDIS) datasets. This overlap could cause a bias towards
237 confounded associations in the two-sample MR [24]. In our MR analysis, the weighted
238 median methods did not show significant results; however, those methods are
239 statistically less powerful than IVW [25]. Large-scale multi-ancestry GWAS datasets for
240 L-2-hydroxyglutarate are essential to construct more robust genetic instruments.

Protein-protein interaction network analysis would be helpful to determine the functional relationship between L2HGDH and the CAD disease module and to identify potential drug targets [26, 27].

5. Conclusion

Our MR result suggests the potential association between genetically proxied inhibition of *L2HGDH* and CAD, though there might be a weak instrument bias. Our findings may have therapeutic implications for L2HGDH inhibitors in CAD. Further large-scale clinical studies are needed to obtain more robust results.

Authorship contribution

Euijun Song designed, performed, analyzed data, and wrote the manuscript.

Acknowledgements

This research received no external funding. This study only used publicly available GWAS summary statistics datasets. The author would like to thank Drs. Loscalzo and Cheng for insightful discussions and comments.

262 ## References

263 1. Oldham, W.M., et al., *Hypoxia-Mediated Increases in L-2-hydroxyglutarate*
264 *Coordinate the Metabolic Response to Reductive Stress.* Cell Metab, 2015.
265 **22**(2): p. 291-303.
266 2. Intlekofer, A.M., et al., *Hypoxia Induces Production of L-2-Hydroxyglutarate.* Cell
267 Metab, 2015. **22**(2): p. 304-11.
268 3. Chakraborty, A.A., et al., *Histone demethylase KDM6A directly senses oxygen to*
269 *control chromatin and cell fate.* Science, 2019. **363**(6432): p. 1217-1222.
270 4. Rzem, R., et al., *A gene encoding a putative FAD-dependent L-2-*
271 *hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria.* Proc
272 Natl Acad Sci U S A, 2004. **101**(48): p. 16849-54.
273 5. He, H., et al., *L-2-Hydroxyglutarate Protects Against Cardiac Injury via Metabolic*
274 *Remodeling.* Circ Res, 2022. **131**(7): p. 562-579.
275 6. Xiao, W., et al., *Immunometabolic Endothelial Phenotypes: Integrating*
276 *Inflammation and Glucose Metabolism.* Circ Res, 2021. **129**(1): p. 9-29.
277 7. Lee, L.Y., et al., *Interferon-gamma Impairs Human Coronary Artery Endothelial*
278 *Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid*
279 *Oxidation.* Circulation, 2021. **144**(20): p. 1612-1628.
280 8. Ference, B.A., et al., *Mendelian Randomization Study of ACLY and*
281 *Cardiovascular Disease.* N Engl J Med, 2019. **380**(11): p. 1033-1042.
282 9. Yarmolinsky, J., et al., *Genetically proxied therapeutic inhibition of*
283 *antihypertensive drug targets and risk of common cancers: A mendelian*
284 *randomization analysis.* PLoS Med, 2022. **19**(2): p. e1003897.
285 10. Sun, L., et al., *Associations of genetically proxied inhibition of HMG-CoA*
286 *reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.* Breast
287 Cancer Res, 2022. **24**(1): p. 12.
288 11. Rosoff, D.B., et al., *Mendelian Randomization Study of PCSK9 and HMG-CoA*
289 *Reductase Inhibition and Cognitive Function.* J Am Coll Cardiol, 2022. **80**(7): p.
290 653-662.
291 12. Bell, A.S., et al., *Comparing the Relationships of Genetically Proxied PCSK9*
292 *Inhibition With Mood Disorders, Cognition, and Dementia Between Men and*

293 *Women: A Drug-Target Mendelian Randomization Study.* J Am Heart Assoc,
294 2022. **0**(0): p. e026122.
295 13. Shin, S.Y., et al., *An atlas of genetic influences on human blood metabolites.* Nat
296 Genet, 2014. **46**(6): p. 543-550.
297 14. Nikpay, M., et al., *A comprehensive 1,000 Genomes-based genome-wide*
298 *association meta-analysis of coronary artery disease.* Nat Genet, 2015. **47**(10):
299 p. 1121-1130.
300 15. Verbanck, M., et al., *Detection of widespread horizontal pleiotropy in causal*
301 *relationships inferred from Mendelian randomization between complex traits and*
302 *diseases.* Nat Genet, 2018. **50**(5): p. 693-698.
303 16. Bowden, J., et al., *Improving the visualization, interpretation and analysis of two-*
304 *sample summary data Mendelian randomization via the Radial plot and Radial*
305 *regression.* Int J Epidemiol, 2018. **47**(4): p. 1264-1278.
306 17. Zhao, Q., et al., *Statistical inference in two-sample summary-data Mendelian*
307 *randomization using robust adjusted profile score.* The Annals of Statistics, 2020.
308 **48**(3): p. 1742-1769.
309 18. Burgess, S., et al., *Sensitivity Analyses for Robust Causal Inference from*
310 *Mendelian Randomization Analyses with Multiple Genetic Variants.*
311 Epidemiology, 2017. **28**(1): p. 30-42.
312 19. Hemani, G., K. Tilling, and G. Davey Smith, *Orienting the causal relationship*
313 *between imprecisely measured traits using GWAS summary data.* PLoS Genet,
314 2017. **13**(11): p. e1007081.
315 20. Rakheja, D., et al., *The emerging role of d-2-hydroxyglutarate as an*
316 *oncometabolite in hematolymphoid and central nervous system neoplasms.* Front
317 Oncol, 2013. **3**: p. 169.
318 21. Jezek, P., *2-Hydroxyglutarate in Cancer Cells.* Antioxid Redox Signal, 2020.
319 **33**(13): p. 903-926.
320 22. Shelar, S., et al., *Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate,*
321 *a Potential Therapeutic Target in Renal Cancer.* Clin Cancer Res, 2018. **24**(24):
322 p. 6433-6446.

23. Shim, E.H., et al., *L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.* Cancer Discov, 2014. **4**(11): p. 1290-8.
24. Burgess, S., N.M. Davies, and S.G. Thompson, *Bias due to participant overlap in two-sample Mendelian randomization.* Genet Epidemiol, 2016. **40**(7): p. 597-608.
25. Bowden, J., *Misconceptions on the use of MR-Egger regression and the evaluation of the InSIDE assumption.* Int J Epidemiol, 2017. **46**(6): p. 2097-2099.
26. Cheng, F., et al., *Network-based approach to prediction and population-based validation of in silico drug repurposing.* Nat Commun, 2018. **9**(1): p. 2691.
27. Lee, L.Y., et al., *Network medicine in Cardiovascular Research.* Cardiovasc Res, 2021. **117**(10): p. 2186-2202.



Figure 1. Overall analysis scheme. (A) Function of L-2-hydroxyglutarate dehydrogenase (L2HGDH) in energy metabolisms. Inhibition of L2HGDH increases blood L-2-hydroxyglutarate levels. (B) We constructed genetic instruments proxied to the *L2HGDH* gene that are associated with blood 2-hydroxyglutarate levels. We then performed two-sample Mendelian randomization analysis to assess the causal effects of genetically proxied inhibition of *L2HGDH* on coronary artery disease and myocardial infarction.

343 **Table 1.** Mendelian randomization (MR) analyses for causal associations of genetically proxied inhibition of *L2HGDH* with

344 coronary artery disease and myocardial infarction.

	Coronary artery disease (60,801 cases, 123,504 controls)			**Myocardial infarction** (34,541 cases, 261,984 controls)		
	OR (95% CI)	**P-value**	**SNPs**	**OR (95% CI)**	**P-value**	**SNPs**
IVW	0.486 (0.242–0.977)	0.043	9	0.676 (0.312–1.463)	0.320	9
IVW (Radial)	0.487 (0.269–0.880)	0.017	9	0.676 (0.361–1.268)	0.222	9
Weighted median	0.762 (0.300–1.937)	0.568	9	0.888 (0.325–2.428)	0.817	9
Maximum likelihood	0.457 (0.216–0.967)	0.041	9	0.655 (0.291–1.476)	0.308	9
MR-RAPS	0.460 (0.202–1.046)	0.064	9	0.681 (0.284–1.630)	0.388	9
MR-Egger intercept*	-0.014 (0.016)	0.396	9	-0.004 (0.017)	0.836	9
MR-PRESSO global[#]	-	0.715	9	-	0.752	9
MR Steiger directionality	-	<0.001	9	-	<0.001	9

345 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted method.

346 *Intercept values are presented with SE.

347 [#]No outlying genetic variants were detected.

348

349 **Supplementary materials**



350

351 **Figure S1.** Genomic positions of nine genetic instruments for genetically proxied

352 inhibition of *L2HGDH*. The genomic positions were visualized using the NCBI Graphical

353 Sequence Viewer (GRCh37, accessed on Oct 29, 2022).

354



Figure S2. Radial inverse-variance weighted (IVW) Mendelian randomization plots for coronary artery disease (A) and myocardial infarction (B). Black dots indicate valid genetic variants. The estimated effect sizes are presented. There is no outlier variant in the present radial plots.

361 **Table S1.** Nine *L2HGDH*-proxied (± 500 kb) genetic variants that are associated with

362 blood 2-hydroxyglutarate levels ($P<0.05$, $r^2<0.3$).

SNP	Position (GRCh37)	EA/OA	EAF	β (SE)*	P-value	F-statistic
rs11628742	chr14:50515075	C/T	0.438	-0.0112 (0.0043)	9.02×10^{-3}	6.784
rs11625406	chr14:50516192	A/C	0.619	0.0070 (0.0033)	3.56×10^{-2}	4.500
rs8017367	chr14:50675487	T/C	0.261	-0.0121 (0.0034)	4.00×10^{-4}	12.665
rs12894758	chr14:50760030	T/C	0.291	0.0135 (0.0034)	6.80×10^{-5}	15.766
rs9323183	chr14:50796881	C/G	0.054	-0.0150 (0.0071)	3.37×10^{-2}	4.463
rs11570815	chr14:50825258	T/A	0.662	0.0094 (0.0033)	4.88×10^{-3}	8.114
rs17791680	chr14:50965445	A/G	0.372	-0.0081 (0.0034)	1.64×10^{-2}	5.676
rs2144975	chr14:50969448	C/T	0.955	0.0170 (0.0075)	2.44×10^{-2}	5.138
rs2012893	chr14:51073443	G/A	0.088	-0.0145 (0.0060)	1.53×10^{-2}	5.840

363 SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effective

364 allele frequency.

365 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

366

367 **Table S2.** Genetic variants associated with blood 2-hydroxyglutarate levels ($P<1x10^{-5}$,

368 $r^2<0.3$).

SNP	Position (GRCh37)	EA/OA	EAF	β (SE)*	P-value
rs10196007	chr2:145329033	C/T	0.184	0.0320 (0.0065)	$7.63x10^{-7}$
rs1568101	chr3:148590090	T/C	0.912	-0.0255 (0.0057)	$8.62x10^{-6}$
rs7725624	chr5:63010725	A/C	0.087	-0.0440 (0.0094)	$3.02x10^{-6}$
rs7702827	chr5:158879869	G/C	0.700	0.0152 (0.0034)	$6.29x10^{-6}$
rs933341	chr7:83743619	G/A	0.760	-0.0166 (0.0035)	$1.56x10^{-6}$
rs8176023	chr7:142642596	G/A	0.072	0.0411 (0.0087)	$2.46x10^{-6}$
rs890519	chr8:18905049	A/C	0.416	0.0147 (0.0033)	$9.06x10^{-6}$
rs10966201	chr9:24079188	C/T	0.345	-0.0151 (0.0034)	$7.11x10^{-6}$
rs11793331	chr9:133298199	T/C	0.024	0.0619 (0.0136)	$5.09x10^{-6}$
rs6484669	chr11:11120287	C/T	0.259	0.0196 (0.0044)	$7.75x10^{-6}$
rs9544785	chr13:78971070	A/C	0.361	-0.0150 (0.0033)	$6.63x10^{-6}$
rs16977497	chr17:71021645	A/G	0.045	0.0538 (0.0122)	$9.91x10^{-6}$
rs6064820	chr20:58206004	T/C	0.723	0.0155 (0.0034)	$4.01x10^{-6}$

369 SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effective

370 allele frequency.

371 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

372

373 **Table S3.** Phenotypes associated with the *L2HGDH*-proxied genetic instruments based

374 on PhenoScanner V2 (accessed on Feb 6, 2023).

SNP	Associated phenotypes ($P<1x10^{-5}$)
rs11628742	-
rs11625406	-
rs8017367	-
rs12894758	Impedance of arm right; Impedance of arm left
rs9323183	-
rs11570815	-
rs17791680	Impedance of arm right; Impedance of arm left; Sitting height; Arm fat-free mass right
rs2144975	Treatment with inderal 10mg tablet
rs2012893	-

375

376 **Table S4.** Leave-one-out sensitivity analyses for the causal associations of genetically
377 proxied *L2HGDH* inhibition with coronary artery disease and myocardial infarction using
378 the inverse-variance weighted method.

	Coronary artery disease		**Myocardial infarction**	
Removed SNP	**OR (95% CI)**	**P-value**	**OR (95% CI)**	**P-value**
rs2144975	0.576 (0.277–1.194)	0.138	0.826 (0.369–1.847)	0.641
rs11570815	0.545 (0.259–1.150)	0.111	0.770 (0.337–1.758)	0.535
rs11625406	0.535 (0.260–1.103)	0.090	0.715 (0.321–1.590)	0.410
rs17791680	0.499 (0.240–1.036)	0.062	0.668 (0.297–1.499)	0.328
rs9323183	0.461 (0.225–0.945)	0.035	0.644 (0.291–1.425)	0.278
rs2012893	0.457 (0.222–0.941)	0.034	0.657 (0.296–1.461)	0.304
rs8017367	0.455 (0.212–0.979)	0.044	0.553 (0.237–1.289)	0.170
rs11628742	0.445 (0.209–0.947)	0.036	0.625 (0.271–1.442)	0.270
rs12894758	0.411 (0.188–0.899)	0.026	0.648 (0.272–1.542)	0.326
None (original)	0.486 (0.242–0.977)	0.043	0.676 (0.312–1.463)	0.320

379 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

380